Ask what is in a cellular treatment

Ask what is causing the soreness

Arthritis can wear down cartilage, the smooth covering at a bone's end. A tendon, the strong band joining muscle to bone, can also get sore.

The location and timing give your examiner useful facts. Soreness after rest may mean something different from soreness that starts with one motion.

You can't sort all of that out from a review. An exam, and sometimes an X-ray, can narrow the cause.

Try the simple care that fits your joint

Give the sore motion a break, but keep moving gently. Too much rest can leave a joint stiff and the nearby muscles weaker.

A regular doctor or nurse can help set safe activity. Medicines, physical therapy, changing daily meals, or a brace may fit some people.

Don't judge progress from one good morning. Notice whether walking, reaching, sleeping, or using the joint gets easier over time.

Ask what the office will prepare

Regenerative treatments are options made from your blood or bone marrow and prepared for use during clinic care. The name alone doesn't say which material an office uses.

Platelet-rich plasma comes from your own blood. The blood is prepared so it holds more platelets, which are small parts involved in clotting.

Ask where the material comes from and who prepares it. You'll also want the risks, cost, recovery time, and choices if it doesn't help.

Get the explanation in plain words before deciding. If you can't explain the treatment afterward, ask again or take more time.

Evidence sources

1. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation.

   Viswanathan S, et al. — Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019.

2. The 2005 International Society for Cellular Therapy statement that first flagged the problem concluded that plastic-adherent marrow cells do not meet generally accepted criteria for stem cell activity, making the name 'mesenchymal stem cell' scientifically inaccurate and potentially misleading to the lay public.

   Horwitz EM, et al. — Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy, 2005.

3. Mesenchymal stromal cells make up only about 0.001 to 0.01 percent of the nucleated cells in bone marrow, so the harvesting and processing technique - aspiration site, syringe size, centrifuge speed and time - materially determines what ends up in the syringe, and no consensus protocol exists.

   Jeyaraman M, et al. — Impact of the Process Variables on the Yield of Mesenchymal Stromal Cells from Bone Marrow Aspirate Concentrate. Bioengineering (Basel), 2022.

4. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023.

5. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025.

6. A 2023 appraisal of 15 randomized and 11 non-randomized trials of culture-expanded MSCs for knee osteoarthritis found function improved relative to control in 11 of 15 RCTs and cartilage protection or repair reported in 18 of 21 imaging studies, but noted the total sample of 610 patients limits any definitive conclusion.

   Copp G, et al. — Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol, 2023.

7. A systematic review of 13 phase I/II randomized trials of MSC injections found 10 of 11 studies reporting cartilage outcomes described a benefit on cartilage volume, morphology or quality - but 16 eligible trials remained unpublished, which is exactly the pattern that inflates an apparent effect.

   Gong J, et al. — Effect of Stem Cell Injections on Osteoarthritis-related Structural Outcomes: A Systematic Review. J Rheumatol, 2021.